

Otto S Hoekstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7548025/publications.pdf>

Version: 2024-02-01

148
papers

10,977
citations

87888

38
h-index

32842

100
g-index

154
all docs

154
docs citations

154
times ranked

14345
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?. Journal of Nuclear Medicine, 2022, 63, 389-395. | 5.0 | 16 |
| 2 | 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 932-942. | 6.4 | 62 |
| 3 | The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. Journal of Nuclear Medicine, 2022, 63, 1424-1430. | 5.0 | 20 |
| 4 | 3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. Diagnostics, 2022, 12, 596. | 2.6 | 1 |
| 5 | Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology, 2022, 40, 2352-2360. | 1.6 | 53 |
| 6 | Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 340-349. | 6.4 | 84 |
| 7 | Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. Journal of Nuclear Medicine, 2021, 62, 332-337. | 5.0 | 53 |
| 8 | Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 1531-1536. | 5.0 | 8 |
| 9 | Spatial concordance of DNA methylation classification in diffuse glioma. Neuro-Oncology, 2021, 23, 2054-2065. | 1.2 | 19 |
| 10 | Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances, 2021, 5, 2375-2384. | 5.2 | 40 |
| 11 | Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example. EJNMMI Research, 2021, 11, 74. | 2.5 | 6 |
| 12 | Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1. | 6.4 | 4 |
| 13 | Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. EJNMMI Research, 2021, 11, 4. | 2.5 | 15 |
| 14 | Diagnostic Performance of [18F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast Cancer. Diagnostics, 2021, 11, 1954. | 2.6 | 10 |
| 15 | Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , . | 0.4 | 0 |
| 16 | Quantitative parametric maps of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 895-903. | 4.3 | 8 |
| 17 | Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro-Oncology, 2020, 22, 412-422. | 1.2 | 59 |
| 18 | Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for ¹⁸ F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 210-216. | 5.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 15-17. | 2.6 | 7 |
| 20 | Repeatability of Quantitative ¹⁸ F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1320-1325. | 5.0 | 22 |
| 21 | Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). <i>Journal of Clinical Oncology</i> , 2020, 38, 3377-3387. | 1.6 | 46 |
| 22 | ¹¹ C-sorafenib and ¹⁵ O-H ₂ O PET for early evaluation of sorafenib therapy. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.251611. | 5.0 | 0 |
| 23 | Imaging Responses to Immunotherapy with Novel PET Tracers. <i>Journal of Nuclear Medicine</i> , 2020, 61, 641-642. | 5.0 | 7 |
| 24 | Quantification of PD-L1 Expression with ¹⁸ F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1455-1460. | 5.0 | 54 |
| 25 | First in man study of [18F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 1047. | 3.3 | 43 |
| 26 | Quantification of ¹⁸ F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1075-1082. | 6.4 | 10 |
| 27 | Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 1102-1110. | 2.6 | 32 |
| 28 | ¹⁸ f-FDG PET/CT Baseline Radiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2020, 136, 27-28. | 1.4 | 1 |
| 29 | Clinical verification of ¹⁸ F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239414. | 2.5 | 6 |
| 30 | PERCISTence: Strength or Stubbornness? (perspective on "From RECIST to PERCIST: Evolving") <i>Journal of Nuclear Medicine</i> , 2020, 61, 199S-226S. | 5.0 | 0 |
| 31 | Performance Evaluation of a Semi-automated Method for [18F]FDG Uptake in Abdominal Visceral Adipose Tissue. <i>Molecular Imaging and Biology</i> , 2019, 21, 159-167. | 2.6 | 3 |
| 32 | Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 65-79. | 6.4 | 55 |
| 33 | Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. <i>EJNMMI Research</i> , 2019, 9, 57. | 2.5 | 8 |
| 34 | Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics. <i>EJNMMI Research</i> , 2019, 9, 12. | 2.5 | 12 |
| 35 | Sensitivity of ¹⁸ F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70. | 2.5 | 10 |
| 36 | Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1545-1552. | 5.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PLoS ONE, 2019, 14, e0222844. | 2.5 | 17 |
| 38 | Interobserver reproducibility of tumor uptake quantification with ⁸⁹ Zr-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1840-1849. | 6.4 | 11 |
| 39 | Early lesion detection with ¹⁸ F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1911-1918. | 6.4 | 55 |
| 40 | Lesion detection by [⁸⁹ Zr]Zr-DFO-girentuximab and [¹⁸ F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939. | 6.4 | 53 |
| 41 | ⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. Journal of Nuclear Medicine, 2019, 60, 1825-1832. | 5.0 | 38 |
| 42 | Assessment of Simplified Methods for Quantification of ¹⁸ F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1221-1227. | 5.0 | 10 |
| 43 | Predictive value of quantitative diffusion-weighted imaging and ¹⁸ F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. European Journal of Radiology, 2019, 113, 39-50. | 2.6 | 38 |
| 44 | Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1495-1505. | 6.4 | 16 |
| 45 | Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹ Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. Journal of Nuclear Medicine, 2019, 60, 902-909. | 5.0 | 50 |
| 46 | Variability and Repeatability of Quantitative Uptake Metrics in ¹⁸ F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol. Journal of Nuclear Medicine, 2019, 60, 600-607. | 5.0 | 16 |
| 47 | Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review. Oral Oncology, 2019, 88, 75-83. | 1.5 | 43 |
| 48 | Healthy Tissue Uptake of ⁶⁸ Ga-Prostate-Specific Membrane Antigen, ¹⁸ F-DCFPyL, ¹⁸ F-Fluoromethylcholine, and ¹⁸ F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117. | 5.0 | 23 |
| 49 | Is ¹¹ Methionine PET an alternative to ¹⁸ F-FDG-PET for identifying recurrent laryngeal cancer after radiotherapy?. Clinical Otolaryngology, 2019, 44, 124-130. | 1.2 | 6 |
| 50 | Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand. EJNMMI Research, 2019, 9, 95. | 2.5 | 7 |
| 51 | Quantitative implications of the updated EARL 2019 PET-CT performance standards. EJNMMI Physics, 2019, 6, 28. | 2.7 | 37 |
| 52 | Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1167-1169. | 5.0 | 32 |
| 53 | Reply: Should we assess repeatability of PET quantitative uptake measurements of each ¹⁸ F-labelled tracer?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1274-1275. | 6.4 | 0 |
| 54 | Repeatability of quantitative ¹⁸ F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 951-961. | 6.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. <i>EJNMMI Research</i> , 2018, 8, 22. | 2.5 | 4 |
| 56 | Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. <i>Molecular Imaging and Biology</i> , 2018, 20, 1025-1034. | 2.6 | 13 |
| 57 | Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 612-615. | 5.0 | 24 |
| 58 | Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma. <i>EJNMMI Research</i> , 2018, 8, 72. | 2.5 | 14 |
| 59 | Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664. | 12.8 | 331 |
| 60 | Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , 2018, 19, e534-e545. | 10.7 | 98 |
| 61 | Use of Diffusion-Weighted Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Combined With Computed Tomography in the Response Assessment for (Chemo)radiotherapy in Head and Neck Squamous Cell Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 780-792. | 1.4 | 9 |
| 62 | Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Research</i> , 2018, 8, 6. | 2.5 | 11 |
| 63 | Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe. <i>EJNMMI Research</i> , 2018, 8, 15. | 2.5 | 29 |
| 64 | Interobserver Agreement of Interim and End-of-Treatment ¹⁸ F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1831-1836. | 5.0 | 23 |
| 65 | Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2307-2317. | 6.4 | 50 |
| 66 | Diagnostic value of diffusion-weighted imaging and 18F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis. <i>European Journal of Radiology</i> , 2018, 107, 20-25. | 2.6 | 31 |
| 67 | The added value of SPECT-CT for the identification of sentinel lymph nodes in early stage oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 998-1004. | 6.4 | 29 |
| 68 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , 2017, 18, e143-e152. | 10.7 | 1,612 |
| 69 | Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e773-e782. | 1.9 | 33 |
| 70 | Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using 18 F-FDG. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 296-305.e2. | 0.4 | 4 |
| 71 | Parametric Method Performance for Dynamic 3-Deoxy-3-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 920-925. | 5.0 | 4 |
| 72 | The adverse impact of surveillance intervals on the sensitivity of FDG-PET/CT for the detection of distant metastases in head and neck cancer patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1113-1120. | 1.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. <i>Acta Oncologica</i> , 2017, 56, 1459-1464. | 1.8 | 11 |
| 74 | Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1884-1891. | 2.4 | 42 |
| 75 | Baseline and longitudinal variability of normal tissue uptake values of [18 F]-fluorothymidine-PET images. <i>Nuclear Medicine and Biology</i> , 2017, 51, 18-24. | 0.6 | 4 |
| 76 | Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI. <i>BMC Cancer</i> , 2017, 17, 256. | 2.6 | 9 |
| 77 | Molecular Drug Imaging: ⁸⁹ Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 711-716. | 5.0 | 69 |
| 78 | Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 961-968. | 1.6 | 14 |
| 79 | [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 8-16. | 6.4 | 20 |
| 80 | Performance of ⁸⁹ Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828. | 2.5 | 50 |
| 81 | Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2534-2534. | 1.6 | 7 |
| 82 | Pharmacokinetics of cetuximab and tumor uptake of ⁸⁹ Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15117-e15117. | 1.6 | 2 |
| 83 | A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9. <i>Oncotarget</i> , 2016, 7, 2123-2134. | 1.8 | 17 |
| 84 | Interaction of quantitative ¹⁸ F-FDG PET/CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 529-535. | 2.0 | 23 |
| 85 | Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸ F-Fluoroazomycin Arabinoside and ¹⁵ O-H ₂ O PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 530-535. | 5.0 | 13 |
| 86 | RECIST 1.1 Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016, 62, 132-137. | 2.8 | 1,143 |
| 87 | Repeatability of Quantitative Whole-Body ¹⁸ F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1343-1349. | 5.0 | 53 |
| 88 | Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with ¹²⁴ I. <i>EJNMMI Research</i> , 2016, 6, 39. | 2.5 | 6 |
| 89 | Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). <i>Neurosurgery</i> , 2016, 79, 535-540. | 1.1 | 19 |
| 90 | ⁸⁹ Zr-Rituximab PET/CT to detect neurolymphomatosis. <i>American Journal of Hematology</i> , 2016, 91, 649-650. | 4.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). <i>Nuclear Medicine and Biology</i> , 2016, 43, 63-72. | 0.6 | 9 |
| 92 | Pretreatment screening for distant metastases in the Dutch head and neck centers: 10 years later. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3287-3291. | 1.6 | 5 |
| 93 | RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145. | 2.8 | 211 |
| 94 | Evaluation of neck node response after radiotherapy: minimizing equivocal results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 605-608. | 6.4 | 3 |
| 95 | ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652. | 7.0 | 74 |
| 96 | Quantitative and Simplified Analysis of ¹¹ C-Erlotinib Studies. <i>Journal of Nuclear Medicine</i> , 2016, 57, 861-866. | 5.0 | 22 |
| 97 | ¹²⁴ I PET/CT to Predict the Outcome of Blind ¹³¹ I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). <i>Journal of Nuclear Medicine</i> , 2016, 57, 701-707. | 5.0 | 39 |
| 98 | Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [¹⁸ F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation. <i>Molecular Imaging and Biology</i> , 2016, 18, 788-795. | 2.6 | 214 |
| 99 | Repeatability of Quantitative ¹⁸ F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 721-727. | 5.0 | 22 |
| 100 | Quantitative Comparison of ¹²⁴ I PET/CT and ¹³¹ I SPECT/CT Detectability. <i>Journal of Nuclear Medicine</i> , 2016, 57, 103-108. | 5.0 | 26 |
| 101 | Effectiveness of an ¹⁸ F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016, 118, 251-256. | 0.6 | 20 |
| 102 | Screening for distant metastases in head and neck cancer patients using FDG-PET and chest CT: validation of an algorithm. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2643-2650. | 1.6 | 16 |
| 103 | Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11553-11553. | 1.6 | 2 |
| 104 | A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5081-5081. | 1.6 | 1 |
| 105 | ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6021-6021. | 1.6 | 2 |
| 106 | Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7504-7504. | 1.6 | 17 |
| 107 | Early ¹⁸ F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0155178. | 2.5 | 4 |
| 108 | Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. <i>Arthritis Research and Therapy</i> , 2015, 17, 266. | 3.5 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Pretreatment screening on distant metastases and head and neck cancer patients: Validation of risk factors and influence on survival. <i>Oral Oncology</i> , 2015, 51, 267-271. | 1.5 | 26 |
| 110 | Quantification of ¹⁸ F-Fluorocholine Kinetics in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 365-371. | 5.0 | 32 |
| 111 | ¹⁸ F-FDG or 3-Deoxy- ¹⁸ F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 216-221. | 5.0 | 24 |
| 112 | A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. <i>Molecular Imaging and Biology</i> , 2015, 17, 714-725. | 2.6 | 10 |
| 113 | Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1829-1839. | 2.0 | 67 |
| 114 | Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3507-3513. | 1.6 | 9 |
| 115 | FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 328-354. | 6.4 | 2,188 |
| 116 | ¹⁸ F-FDG SUV in the primary tumor and lymph node metastases is not predictive for development of distant metastases in high risk head and neck cancer patients. <i>Oral Oncology</i> , 2015, 51, 536-540. | 1.5 | 3 |
| 117 | Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and ¹⁸ F-FDG-PET/CT. <i>Oral Oncology</i> , 2015, 51, 541-547. | 1.5 | 31 |
| 118 | ⁸⁹ Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 30384-30393. | 1.8 | 106 |
| 119 | Effects of Reusing Baseline Volumes of Interest by Applying (Non-)Rigid Image Registration on Positron Emission Tomography Response Assessments. <i>PLoS ONE</i> , 2014, 9, e87167. | 2.5 | 2 |
| 120 | Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. <i>British Journal of Cancer</i> , 2014, 111, 749-755. | 6.4 | 25 |
| 121 | Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study. <i>Radiology</i> , 2014, 273, 539-548. | 7.3 | 82 |
| 122 | Parametric Methods for Quantification of ¹⁸ F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1772-1777. | 5.0 | 12 |
| 123 | Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2014, 83, 1144-1151. | 2.6 | 16 |
| 124 | Assessment of Simplified Methods to Measure ¹⁸ F-FLT Uptake Changes in EGFR-Mutated Non-Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1417-1423. | 5.0 | 17 |
| 125 | Sentinel lymph node biopsy in clinically NO T1-T2 staged oral cancer: The Dutch multicenter trial. <i>Oral Oncology</i> , 2014, 50, 1020-1024. | 1.5 | 75 |
| 126 | Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058. | 1.6 | 1,269 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. <i>Lung Cancer</i> , 2014, 85, 205-212. | 2.0 | 23 |
| 128 | PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11001-11001. | 1.6 | 13 |
| 129 | ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11102-11102. | 1.6 | 2 |
| 130 | Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer. <i>Quantitative Imaging in Medicine and Surgery</i> , 2014, 4, 239-50. | 2.0 | 24 |
| 131 | SAT0531â€¦Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A761.2-A761. | 0.9 | 0 |
| 132 | Towards qualification of FDG PET as biomarker of response to neo-adjuvant therapy: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22128-e22128. | 1.6 | 0 |
| 133 | First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. <i>Annals of Oncology</i> , 2011, 22, 559-566. | 1.2 | 70 |
| 134 | Monitoring Response to Antiangiogenic Therapy in Nonâ€“Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI. <i>Journal of Nuclear Medicine</i> , 2011, 52, 48-55. | 5.0 | 98 |
| 135 | Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma., <i>Blood</i> , 2011, 118, 3658-3658. | 1.4 | 0 |
| 136 | Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. <i>Oral Oncology</i> , 2009, 45, 386-393. | 1.5 | 83 |
| 137 | The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2320-2333. | 6.4 | 343 |
| 138 | Systematic review: Accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. <i>Head and Neck</i> , 2008, 30, 889-897. | 2.0 | 41 |
| 139 | Improved detection of recurrent laryngeal tumor after radiotherapy using 18FDG-PET as initial method. <i>Radiotherapy and Oncology</i> , 2008, 87, 217-220. | 0.6 | 21 |
| 140 | Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. <i>Radiotherapy and Oncology</i> , 2008, 87, 221-229. | 0.6 | 97 |
| 141 | Quantitative Issues in Response Measurement by PET. <i>PET Clinics</i> , 2008, 3, 5-11. | 3.0 | 2 |
| 142 | Reproducibility of Tumor Perfusion Measurements Using ¹⁵ O-Labeled Water and PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1763-1768. | 5.0 | 44 |
| 143 | A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. <i>Contemporary Clinical Trials</i> , 2007, 28, 705-712. | 1.8 | 20 |
| 144 | Evaluation of Cost-effectiveness of FDG-PET in Nonâ€“Small Cell Lung Cancer. <i>PET Clinics</i> , 2006, 1, 329-337. | 3.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. European Archives of Oto-Rhino-Laryngology, 2004, 261, 417-22. | 1.6 | 43 |
| 146 | How to perform a comprehensive search for FDG-PET literature. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 91-97. | 2.1 | 36 |
| 147 | Primary staging and follow-up of high risk melanoma patients with whole-body ¹⁸ F-fluorodeoxyglucose positron emission tomography. , 1999, 85, 1199-1200. | | 54 |
| 148 | Sentinel Node Biopsy in Melanoma Patients: Dynamic Lymphoscintigraphy Followed by Intraoperative Gamma Probe and Vital Dye Guidance. World Journal of Surgery, 1997, 21, 788-793. | 1.6 | 141 |